List of Therapeutic Companies in China - 196

About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world's leading bio-pharmaceutical company in China.

ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners.

Accro Bioscience (Suzhou) Limited is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. The company is a leading biotechnology company based in China and is privately-held. Accro Bioscience is dedicated to the development of treatments for inflammatory conditions and has recently announced a Series B funding round of over $50 million.

Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

We are a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. We are committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform cancer into manageable conditions.

The company develops vaccines toinduceimmunotolerance or stimulate T cells, for certain diseases. Beijing Advaccine is also collaborating with Inovio Pharmaceuticals on a novel vaccine to prevent COVID-19.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions.

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Alpha Biopharma – Specialized in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical company/R&D institute.

AlphaMa is a pioneering drug R&D company based in Suzhou, China, established in 2018. With artificial intelligence (AI) as the driving technology, DNA-encoded library (DEL) technology is cross-applied to establish a cutting-edge Intelligent DEL (iDEL) platform(including the first-class technology of on-demand DEL synthesis, DEL screening, hit confirmation, macrocyclic peptide DELs, customized glue library, etc.). The iDEL platform at AlphaMa features first-class DNA-encoded library (DEL) technology specializing in small molecule, macrocyclic peptide and covalent hit discovery, etc. With its mature screening technology and high success rate, providing global partners with a cost-effective and efficient one-stop DEL screening service. Our flexible service model, diversified services and excellent service system cover all stages of early drug discovery. We provide flexible and cost-effective approaches to meet customers' diverse needs with professional technology and high-quality services. AlphaMa is your ideal partner for drug discovery, assisting you in accelerating the drug discovery process. Reach out to learn more: liuyulin@aiphama.cn

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

Angel Pharmaceuticals was founded in 2020, focusing on develop, produce and sale of innovative oncology drugs. We develop four innovative drugs in China and build a platform for new drugs, aiming at the unmet medical needs of China's cancer drug market, and build China's first-class innovative drug company. Our management team has decades of clinical and drug research and development experience, which lays a solid foundation for the development of new drugs.

Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.

Zhifei is a high-tech biological enterprise integrating the R&D, production, distribution as well as import & export to mainly produce vaccines for human use.

At Anlong Bio, patients are our priority. Since launching, our goal has been to deliver transformative gene therapy medicines to patients faster and at low cost, in China and globally. We aim to provide unmatched access to treatments for patients through our extensive resources, our experienced leadership and advisory teams, and our trusted network of partners.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. The company also has a non-therapeutics division focused on the development of surgical robotics and medical devices.

Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients. In the past two years, Argo biopharma has built a rich and differentiated pipeline of siRNA drug candidates for a wide range of indications, utilizing its industry-leading siRNA platform technology known as RADS (RNA molecules with superior Activity, Durability, and Safety). Led by an experienced and professional team, Argo Biopharma has demonstrated scientific excellence in siRNA drug discovery and strong execution in advancing potential therapeutic products from discovery to clinical stage.

上海爱科百发生物医药技术股份有限公司 总部地址：中国上海浦东新区盛荣路388号25号楼 爱科百发是一家专注于呼吸系统、肺部疾病以及儿科疾病方面未被满足的重大医疗需求的生物医药公司。公司总部位于上海，研发中心位于苏州Biobay，并在北京和悉尼设有办公室。自2014年成立以来，公司通过自主研发和外部引进相结合的研发模式，开发出坚实且具有高度差异化的产品管线，涵盖多种候选药物产品，包括以Ziresovir为首的RSV药品组合，以及以AK3280为重点的抗纤维化药品组合。爱科百发旨在成为全球领先的在呼吸、肺部及儿科疾病领域集新药研发、生产及商业化的一体化生物医药平台企业。

Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. The Company is dedicated to developing and bringing to market therapies that target each class of molecular pathways regulating apoptosis, or programmed cell death, in a wide range of indications. Headquartered in Suzhou, China, we are a rapidly growing company with offices in three countries. Ascentage Pharma has built a pipeline of seven clinical drug candidates, including novel, highly selective and potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, additional apoptotis inhibitors targeting IAP and MDM2-p53 proteins. The pipeline is balanced by next-generation tyrosine kinase inhibitors (TKIs) aimed at treatment induced resistance mutations. Ascentage Pharma is conducting more than 40 clinical trials in specific regions worldwide.

Developer of targeted radionuclide therapies used to treat cancer. The company develops radioactive drugs and other nuclear therapies.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio's strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.

Avistone is a commercial real estate investment firm specializing in the acquisition and management of multi-tenant industrial/warehouse properties. They focus on stabilized multi-tenant industrial properties and have a history of success achieving historical returns of 19.01%. Avistone was founded in 2013 and is rapidly growing in the commercial real estate investment industry.

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

On August 20, 2024, Base Therapeutics announced that its AccuBase® base editor has officially received authorization for two patents from the United States Patent and Trademark Office (USPTO). This marks that both of Base Therapeutics' AccuBase® technologies have secured patent protection in China and overseas markets. Base Therapeutics' strategic positioning in the gene editing field is at the forefront internationally, making it one of the biopharmaceutical companies with the most authorizations domestically and abroad.

Shanghai BDgene Therapeutics Co., Ltd. was established in 2018. The founder team includes top scientists in the field of gene therapy, industrial experts with a background in international pharmaceutical companies, toxicology and safety pharmacology experts with preclinical drug evaluation experience.

BeBetter Medicine Technology Co., LTD. is a rapid growth novel drug discovery and development company located in Guangzhou, China. It was founded in 2012 by overseas returnees and aims to create advanced novel medicines to treat cancer and other severe diseases. The company has strong expertise and outstanding facilities to conduct comprehensive pharmaceutical research from drug design, synthesis to clinical development. Currently there are eight innovative drug candidates with own IP rights are in clinical or IND stages. Among them, BEBT-908 has entered the pivotal phase II trial for the treatment of lymphoma. BEBT-209 and BEBT-109 are in the phase Ib/II trial for the treatment of breast cancer and lung cancer, respectively. The company is expected to have a number of new drugs on the market in the next few years.

BeiCell Therapeutics is a revolutionary cell therapy company stemming from Prof. Hongkui Deng's lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.

Beihai Biotech is a clinical-stage biopharmaceutical company based in Zhuhai, China, that researches, develops, and produces safe anti-cancer drugs. The company is focused on developing innovative anti-tumor drugs to improve tumor treatments and provide a better life for patients.

NeoX Biotech is a China-based biotechnology company that combines AI with biophysics for the discovery and development of macromolecular drugs to treat cancer.

Founded in 2018, Belief BioMed is aiming to become a globally leading gene therapy company by being committed to providing innovative therapies with improved efficacy for monogenic disorder diseases, age-related degenerative diseases, and certain malignant diseases through its AAV vector technology from early discovery to commercialization. The R&D and production strengths of Belief BioMed have been recognized by top investment institutions and enterprises. Belief BioMed has offices, research centers and manufacturing facilities in Shanghai, Hong Kong, Beijing and Suzhou China and North Carolina US.

Berry Oncology, founded in 2017 as a member company of Berry Genomics, focuses on genomic testing of cancers.

BioCity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world's leading open drug innovation platform. The company is committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and Nephropathy. Through internal research, open innovation platform and collaborations, BioCity has established a pipeline of more than 10 innovative programs including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugate (ADCs).

RNAi

Biomissile is a biopharmaceutical company that focuses on the drug development.

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support four marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,300 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery.

BioRegen is specialized in innovative and novel therapeutic biomaterials and regenerative medicine. Based on its unique and proprietary "self-crosslinking" technology platform, the company has developed several products - HyaRegen Gel , MateRegen Gel and PureRegen Gel for broad clinical application such as general surgery, GYN/OB and ENT surgeries and launched in many countries over the world. The gel can prevent postsurgical adhesion and promote the intimal regeneration.

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Bivision is a China-based biopharmaceutical company that develops visually targeted radionuclide therapies for the treatment of cancer across the globe.

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of anti-tumor biotherapeutics. With the core value of 'Together, We Improve Human Health,' the company focuses on multi-level collaborations and developments to advance its mission.

Brise Pharma is a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatments for chronic pain.

At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 5 Investigator-Initiated clinical Trials (IIT) in 8 leading hospitals in China, with many pipeline projects have entered into IND application stage. Among them, gene editing projects for β-thalassemia, PD1 knockout non-viral targeted integration CAR-T and UCART have achieved excellent clinical results and have published several academic papers in famous academic journals such as Nature Medicine and Nature biotechnology. BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms, and has a 7000 square meter GMP pilot plant and an operating team of more than 200 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors!

CANbridge Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing innovative medicines to address unmet medical needs.

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology as well as formulation and delivery technology.

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

CellOrigin Biotech has a long term focus on iPSC-derived innate immune cells and its applications in new cancer immune cells. Dr. Jin Zhang, the scientific co-founder of CellOrigin used to be trained as a research fellow at the Boston Children’s Hospital and Harvard Medical School. His team worked closely with clinicians at the First Affiliated Hospital of Zhejiang University and for the first time reported the induced pluripotent stem cell or iPSC-derived CAR-macrophages (CAR-iMac), and its applications in cancer immunotherapies. As for now, CellOrigin Biotech holds its proprietary technologies for iPSC-derived CAR-Macrophage. With this platform, they are collaborating with research groups in genome engineering and synthetic biology at Harvard and MIT to fully unleash the potential of iPSC-derived immune cells, which are highly editable, expandable and clonal. Eventually, they would like to achieve a goal of bring more effective, universal and safe immune cell products to cancer patients, especially for those with solid tumors. The investigator initiated trials has been initiated at the First Hospital of Zhejiang University. The core proprietary technology platform and the core patents including the engineered macrophages from pluripotent stem cells has been authorized and is in the process of entering the US, Australia, South Africa, etc.

Shandong Taibang Biological Products is a biotechnology company based out of Taian City, SHD, China.

Chongqing Sintaho Pharmaceutical Co., Ltd. takes chemistry as the core, located at Chongqing International Biological City in China, jointly founded by Chongqing Taihao Pharmaceutical Co., Ltd. (established in 2004) and a US new-drug enterprise in July 2016. With 260+ employees integrated with R&D, production, regulatory affairs, and marketing, Sintaho commits itself to the global market, particularly the US, EU, and China. Sintaho specializes in chemosynthetic APIs (therapeutic areas mainly contain oncology, nervous system and metabolic diseases), with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs. Sintaho contributes to being the most dependable partner for global pharmaceutical companies.

Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company employing its proprietary transformer base editing (tBE) technology to pioneer next-generation gene editing therapies. Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrates its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies. Proof-of-concept (POC) data in mice for in vivo pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases. Ex vivo multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function in vivo compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development. tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs or adeno-associated viruses (AAVs). We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases. Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.

C Ray Therapeutics, established in 2021 and headquartered in Chengdu Medical City, is incubated by internationally renowned investment institutions 6 Dimensions Capital. Since its establishment, C Ray has been dedicated to the field of radiopharmaceuticals, aiming for world-class standards. Within just over three years, the company has achieved a series of landmark accomplishments: > Construction of a nearly 30,000 square meter R&D and production base for radiopharmaceuticals. > Obtaining the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise. > Establishing a leading platform with advanced global equipment, cutting-edge technology innovation, and comprehensive functional support in the field of radiopharmaceuticals.

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company based in Shijiazhuang, Hebei, China. The company focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. With a strong emphasis on innovation, CSPC has a robust research and development team of over 2,000 members, including many with advanced degrees and international experience. Their R&D efforts span multiple locations, including Shijiazhuang, Shanghai, Beijing, and the United States. CSPC offers a diverse array of pharmaceutical products, including finished drugs like capsules, tablets, and injections, as well as bulk drugs such as active pharmaceutical ingredients. Their product range addresses various therapeutic areas, including oncology, cardiovascular health, respiratory conditions, anti-infectives, and diabetes management. The company also has an extensive pipeline of over 300 projects focused on innovative drug development, highlighting its commitment to advancing healthcare solutions. CSPC's products are available in multiple regions, including the Americas, Europe, and Asia, serving a broad customer base in the healthcare sector.

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received ten NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Cure Genetics is an innovative gene therapy company focused on the application and development of viral delivery systems and gene editing systems. In response to the clinical needs of complex genetic diseases and refractory tumors, it has conducted extensive international cooperation and established a breakthrough product pipeline, striving to become a benchmark in the global gene therapy field. The company was founded in 2016 and is located in Suzhou Industrial Park. It brings together core talents from different fields at home and abroad to build a complete differentiated platform around the AAV virus delivery system and CRISPR gene editing system. Possess core independent intellectual property rights and create core competitive barriers. At the same time, the company has established a scientific committee composed of internationally renowned scientists and executives from multinational pharmaceutical companies to lay a solid foundation for technology commercialization.

Biotechnology company focusing on development and registration of innovative medicines in oncology and immunology.

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物 映恩生物（Duality Biologics）是一家临床阶段的创新生物药企，专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物（ADC）技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台，以开发下一代“超级ADC”分子，包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作，并在全球开展多个国际多中心（MRCT）关键性临床研究。致力于成为世界领先的ADC公司。 如需更多信息，请访问www.dualitybiologics.com

Eachy Biopharmaceuticals, Ltd is a ISO 13485 qualified company focused on developing and producing in vitro diagnostics for the prognosis of cardiovascular diseases, metabolic syndrome and the diagnosis of inflammatory diseases.AccuRapid SARS-CoV-2 IgM/IgG Test Kit (Lateral Flow Immunoassay) - EU CE Mark 32020

Eccogene is focused on building a pipeline of best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions with the goal of improving care and expanding access to cost effective medicines for millions of patients worldwide. Since our inception, our team has been dedicated to discovering safer and more effective oral therapies that may be used alone or synergistically with a GLP-1 receptor agonist to treat conditions beyond obesity. Among our core strengths is our team -- comprised of individuals with world-class expertise in translational research and small molecule discovery -- as well as our deep understanding of diabetes, weight loss and cardiometabolic disease pathways. Our oral small molecule GLP-1 receptor agonist, ECC5004, is a potentially best-in-class asset, which we licensed to AstraZeneca. To expand on the opportunity in cardiometabolic disease, we are also advancing clinical programs targeting THR-β and SSAO, as well as preclinical programs targeting proven pathways, such as GIP. We invite you to read more about our company on our website at www.eccogene.com

EdiGene is a clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases.

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research.

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships.

Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative therapeutics for the treatment of cancer and autoimmune diseases.

Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The company’s innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs. Two programs have advanced to the clinical stage: (1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China (2) neurovascular AMD (wet AMD) rAAV gene therapy in USA The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Exegenesis Bio has raised over $150 M since inception in 2019 and currently employs over 200 scientific and operations staff worldwide. Website: https://www.exegenesisbio.com/ Contacts: Company Information: Contact@ExegenesisBio.com Business Development: BD@ExegenesisBio.com Careers: Careers@ExegenesisBio.com

Forward Pharma is an innovative pharmaceutical company that focuses on the independent research and development of drugs. It has a dual-platform approach that covers the entire drug development process, from target validation, drug discovery, early development, translational medicine research, preclinical studies, and clinical development. The company is headquartered in Nanshan, Shenzhen, with international operations and research teams in Shanghai and Shenzhen. Over the past seven years, relying on its self-built chemical small molecule and monoclonal antibody drug discovery platform, Forward Pharma has established a product matrix consisting of more than 10 innovative drugs in over three major solid tumors and autoimmune diseases.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

Frontera is a leading clinical-stage biotechnology company that seeks to develop the best gene therapy medicines to improve the lives of patients across multiple disease areas. Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).

Gensciences, also known as Shengsi Biopharma, is an innovative biopharmaceutical company based in Nantong, China. The company is privately held and has received venture capital backing. Gensciences is dedicated to improving the lives of people living with hemophilia and has received hundreds of millions of yuan in Series D financing. The company's innovative development strategy focuses on drug pipelines, patents, and clinical trials for hemic and lymphatic diseases. For more information, you can visit their official website at http://shengsi.haio.cn/index.html.

loria Biosciences (誉衡生物) is a commercial stage biopharma company founded in 2016, bringing together a seasoned development and management team with global versions, and dedications to developing patient-centered treatments. In 2021, Gloria Bio has successfully launched and commercialized a novel, fully human anti-PD-1 mAb, zimberelimab ("Yutuo", "誉拓”), for the treatment of relapsed or refractory classical Hodgkin’s lymphoma, which demonstrated an overall response rate (ORR) of 92.86%, DCR of 96.43%, and 12 month overall survival rate of 99% with improved long-term survival benefits for patients. Zimberelimab is also designated as Breakthrough Therapy by China's Center for Drug Evaluation for the treatment of recurrent or metastatic cervical cancer, which has been approved in July 2023, marking the first and only PD-1 mAb approved in China for cervical cancer, and third globally. Currently, zimberelimab is being evaluated in multiple types of cancer, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast, head and neck, and renal cell cancers, etc. It is also being studied in combinations with multiple innovative drugs, targeting CD47, CD73, TIGIT, A2aR, CCR8, LAG-3, CD40, CD39, Trop-2, CAR-T, HER-2 ACD and Neo-T, etc. Gloria Biosciences is striving to build a pipeline with more effective treatment alternative for cancer patients, including LAG-3 and other innovative monoclonal and biospecific antibodies.

Gmax Biopharm LLC. has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. The company is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) and has developed the world's first ETa-specific monoclonal antibody. Gmax Biopharm has also partnered with Sino Biopharmaceutical Ltd. and has a strong pipeline of products in development.

GrandOmics focuses on the application of long-read sequencing technology；we developed sequencing solutions for different biology research fields by integrating the advantages of multiple sequencing platforms, including NGS and Long-read Sequencing. GrandOmics also actively engaged in the independent development of bioinformatics software and explore the application of long-read sequencing technology in clinical medicine. In response to the data processing problems of the long read sequencing technology in the application fields of animal and plant genome research, pathogenic microorganism detection, and clinical testing, we have developed NextDenovo, NextPolish, GrandBox, GrandPathogen and other bio-information algorithms and platforms to analysis genomic data. Contact us now at inquiry@grandomics.com. We are so glad to assist your genomics research – we’d love to hear from you!

Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit’s non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial. Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.

Gritgen Therapeutics (here in after designated as "Gritgen") was founded in China and is a biotechnology company focused on gene therapy. They have launched a commercial GMP facility in China and have opened a good manufacturing practice (GMP) facility in Suzhou Industrial Park. Gritgen provides an important vector foundation for the company to realize gene therapy for hemophilia A. The company has also launched a Phase 1 clinical trial to assess the safety of gene therapy for hemophilia A.

Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer. Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac) ; (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST) . The two platforms have been fully developed to the clinic-ready stage. As a result, an independently-owned intellectual property portfolio has been constructed which spans across the whole spectrum of TCR-related technologies including the identification of tumor-specific antigens, antigen-specific TCRs, and the optimization of antigen-specific TCRs in terms of affinity and stability, etc. To date, many domestic and PCT applications have been filed. Housing several state-of-the-art laboratories, XLifeSc is capable of offering a broad range of R&D services, including (1) large scale GMP grade lentivirus production; (2) target identification and lead optimization; (3) efficacy validation and safety testing in cell lines and animal models; (4) clinical trial development; and (5) market entry planning. These capabilities and services can be either accessed as flexible stand-alone services on demand or as a part of integrated drug discovery programs. To meet the needs of different partners, we welcome all types of alliance opportunities such as out-license, co-development, and co-marketing.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd. was established in July, 1995. It has developed into a new pharmaceutical group featuring R&D, manufacture, sales and pharmaceutical investment of drugs. There are more than 40 products launched into the market which cover six therapeutic categories: oncology, antibiotics, psychotropic, antidiabetics, gastro-intestinal and cardiovascular area. Since its inception, Hansoh has evolved into a flagship enterprise for R&D and production in China, a Top 30 enterprise of China's Pharmaceutical Industry, and one of the most innovative pharmaceutical enterprises in China. Adhering to the concept of management innovation, technology innovation and product innovation, Hansoh will accelerate collection and fusion of development factors including top-level talents, innovative technology and lean manufacturing, along with peers in the international pharmaceutical field, hand in hand and shoulder by shoulder, to jointly endeavor bravely to contribute wisdom and strength to health of mankind.

Xueji Bio is a stem cell biopharmaceutical company founded by overseas returnees. It is committed to regenerating blood cells through stem cells for cell therapy of various diseases and related drug research and development. The company's founding members are from famous universities at home and abroad, such as Stanford University, Harvard University, and Peking University. Based on the world's leading stem cell directed differentiation system, Xueji Bio uses in vitro produced platelets as its lead product to address the urgent need for platelets in diseases such as cancer, liver disease, critical illness, and blood diseases, as well as develop innovative drugs for various platelet abnormality-related diseases.

Hengsai Bio is a tumor immunotherapy developer that engages in R&D and industrialisation of a new generation dendritic cell tumor vaccines.

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Shanghai Weizhizhuo Biotechnology Co., Ltd. was established in 2015. It has production lines and R&D centers in the core area of ​​Shanghai Jiading Industrial Park and Shanghai Zhangjiang High-tech Park. The company has internationally leading cell differentiation and production technology and is a new biomedical technology company focusing on severe liver diseases and cell therapy. The company's founders come from world-class academic research institutes and top pharmaceutical companies, and are committed to developing the world's most advanced innovative biomedical technologies and products to provide patients with better clinical solutions. China is a country with a high incidence of liver disease, with 500,000 to 1 million new cases of liver failure each year, and the 28-day mortality rate of patients with acute liver failure is as high as 50%. The most effective treatment option at present is liver transplantation, but the high cost of treatment and the shortage of liver sources mean that only about 5,000 patients can undergo liver transplantation each year. In addition, the use of physical adsorption and plasma exchange cannot effectively remove toxins from the blood and promote the recovery of liver function. The team led by Hui Lijian, a researcher at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, has collaborated with many institutions to break through the in vitro culture technology of "hepatocyte-like cells" and construct hiHep cells with the world-leading direct transdifferentiation technology. This technology also won the honor of "Top Ten Advances in Chinese Science" in 2011. With this as the core, Shanghai Weizhizhuo Biotechnology Co., Ltd., which has obtained the exclusive global license for this technology, has built a new HepaCure bioartificial liver support system, which provides a new and effective treatment for patients with liver failure caused by severe liver disease. The HepaCure bioartificial liver is an in vitro liver function support system that can replace liver function in a short period of time, promote the recovery of autologous liver function in patients with liver failure, and buy time for patients planning liver transplantation to wait for a suitable liver source. It is like a small liver dialysis machine. During the dialysis process, it not only detoxifies the blood, but also supplies nutrients to the liver.

Clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company's lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome of all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumor cancers. Additional programs include immunoliposomes designed to improve efficacy and toxicity of existing of existing immuno-oncology technologies including ADCs and CAR-T.

HighTide Therapeutics, Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Jiangsu Hillgene BioPharma is a leading CDMO platform for cell therapeutics. Our shareholders include China SME Development Fund, Guokejiahe Fund, Haier Capital, Huapont life science, China Capital Management, etc. The company is headquartered in Wuzhong District of Suzhou, the beautiful shore of Taihu Lake, with a registered capital of 100 million RMB. At present, a nationwide network of production bases has been formed initially, consisting of the headquarters in Suzhou (10000m2 GMP facility constructed) and the production base in Shenzhen (8000m2 GMP facility under construction). Meanwhile, the production base in North Carolina that is under construction contributes to the global layout     Hillgene focuses on cell therapeutics' and  particular plasmid production platforms, suspended and serum-free culture of viruses, and fully enclosed process development of cells, providing one-stop services from discovery to product delivery. We have helped several partners successfully develop drugs including CAR-T, TCR-T, and stem cells. And we are dedicated to pushing more projects to a new milestone quickly and bringing more cell therapy drugs into the market to let patients enjoy the products. Cell therapy innovation inspired.

Himalaya is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide. The company has exclusive rights to deploy CAB antibodies in its territories, with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively.

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, HopeMed is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations. Strategically, we are building a robust pipeline in the field of endocrine, cardiovascular and metabolic diseases, with a special focus on women’s health, through internal R&D capabilities, access to external technology platforms to enable a variety of molecular modalities, as well as in-license of complementary and differentiated assets to address unmet medical needs.

Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.

Hrain is supported by authoritative scientific advisory committee, cooperating with international top universities and domestic research institutes, including University of Southern California, Duke University, University of California, Los Angeles, Cell and Gene Therapy Center of Academy of Military Medical Sciences, Cancer Diagnosis and Treatment Institute of Xinqiao Hospital, etc.

Huadao Biopharma is a biomedical company that specializes in cellular immunotherapy. It is headquartered in Shanghai, China and is primarily involved in drug discovery.

Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders. In order to meet the highest international standards, Hua Medince developed a powerful internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).

HuidaGene Biotechnology Co., Ltd (辉大基因) is a global biotechnology company focusing on the discovering, engineering, and developing CRISPR-based genetic medicine to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patient's needs globally with various preclinical therapeutic programs covering ophthalmology, otology, myology, and neurology. Company's CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. We are committed to transform the future of genome-editing medicine.

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China.

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, as well as IASO’s leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM), which was granted Breakthrough Therapeutic Designation by China’s National Medical Products Administration (NMPA) in February 2021. In addition. The company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021.

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company’s product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Immorna is a rapidly expanding biotechnology company, focusing on the development of mRNA-based therapeutics and vaccines. Immorna is utilizing multiple mRNA platforms, including conventional, self-replicating and circular mRNA. Since it’s founding in 2019, Immorna has built a robust CMC platform for mRNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of mRNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse mRNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology and infectious disease drug candidates into their clinical stages.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an clinical-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells. To achieve these goals, we have established several proprietary platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells, to fulfill the cancer-killing tasks. Macrophages play critical roles in fighting cancer through phagocytosis followed by tumor antigen presentation to T cells, which in turn destroy antigen-expressing tumor cells. However, cancer cells have evolved to evade immune surveillance, by mechanisms such as over-expressing CD47 and inhibiting phagocytosis via interaction with signal regulatory protein (SIRPα) on macrophages. We are developing a pipeline of compounds for reversing cancer cell-induced inhibition of innate immunity. NK cells are innate defense mechanisms of the body against viral infection and cancer, which directly target pathogenic cells without requirement for MHC recognition. We have established proprietary platforms and target-activated NK (TANK™) cell therapy for treatment of both leukemia and solid tumors. ImmuneOnco is actively advancing pipelines of proprietary platform-based compounds targeting a broad range of canncer indications.

The company is focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immuno Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.

Small Molecules

Imunopharm (Beijing Yimiao Shenzhou Pharmaceutical Technology) is a clinical-stage biopharmaceutical company founded in Beijing in 2015. Committed to the mission to cure the incurable, Imunopharm focuses on applying innovative cell and gene therapies to help patients prevail over serious diseases such as cancer and autoimmune disorders. Imunopharm has established an integrated autonomous platform required for the research and industrialization. Our pipeline covers hematologic malignancies such as lymphoma, leukemia, and multiple myeloma, as well as solid tumors including liver cancer and colorectal cancer. Clinical data of CAR-T products have been presented multiple times at international conferences such as ASCO, ASH, IMS, and ESMO. To date, Imunopharm has completed 9 rounds of strategic financing, and has obtained the CAR-T drug production license with 7 China INDs. At present, Imunopharm has emerged as a cornerstone in CAR-T therapy in China.

Founded in 2022, InflamaX is a clinical-stage biotechnology company located in Guangzhou that specializes in making new medicines that target immuno-inflammation as a means for treating various diseases including cancers, pain, neurological diseases, and osteoarthritis. It is our belief that the tissue microenvironment determines how the immune system responds to its surrounding environment. Small changes in the extracellular matrix can cause an over-reaction or under-reaction in the immune/inflammatory response resulting in disease. Our drugs target key mechanisms and pathways in the tissue microenvironment that correct this incorrect immune/inflammatory response. We currently have 4 clinical candidate drugs in our portfolio and also have a preclinical drug discovery arm that is making new compounds against various immuno-inflammation-based targets.

InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

北京因诺惟康医药科技有限公司（Innovec Biotherapeutics）是一家从事基因治疗技术和产品研发的公司，成立于2020年8月，位于北京生命科学园，公司创始人为多位留美归国的生物医药专业的博士，有着丰富的病毒学、基因治疗研发和生产、临床医学等方面的经验。公司于2021年6月完成数千万天使轮融资。参与天使轮投资的基金主要是具有丰富医药行业投资经验的知名的创投基金和投资人。 因诺惟康目前有诸多基因治疗的产品管线储备，大部分集中于眼科和神经科领域，公司生物医药技术包括新型病毒载体的设计和开发、基因编辑药物开发，临床级病毒载体的生产和应用，研究遗传疾病的自然发生过程、特征及突变基因，建立遗传疾病相关的动物模型。公司主要项目处于临床前的研究阶段。

Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.

A company focusing on innovative drug research and development for pain treatment.

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

Founded in 2018, Jianda Biopharmaceuticals (Nanjing) Co., Ltd. is a biopharmaceutical company founded by domestic and foreign vaccine research and development, industrialization and commercialization experts and an elite team in the pharmaceutical industry. Its headquarters is located in the Biopharmaceutical Valley of Nanjing Jiangbei New District. Driven by independent innovative technologies, Jianda Biopharma focuses on the development and industrialization of new human vaccines and biopharmaceutical products such as tumor treatment. Since its establishment, the company has devoted itself to research and development and established a DC-targeted VLP vaccine technology platform and a circular mRNA vaccine technology platform with independent intellectual property rights. A series of innovative products based on platform technologies are in the POC, pilot production and pre-IND stages. In 2021, the company completed its angel round of financing, with Shenzhen Songshan Capital and Dongguan Juying Capital investing 33 million yuan, pushing multiple of the company's products from R&D to pre-IND. The company focuses on the field of life and health, introduces company teams, insists on pioneering and innovation, deploys multiple product pipelines, and strives to bring new vaccines developed to the market to benefit human life and health.

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. (hereinafter referred to as Recbio or the Company; stock code: 2179.HK) is an innovative vaccine company driven by self-developed technologies. We are dedicated to the R&D, production and commercialization of innovative vaccines, leveraging our core technology platforms (novel adjuvant, protein engineering, immunological evaluation). With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios consisting of ten-odd differentiated vaccines, covering cervical cancer, shingles, COVID-19, TB and other high-burden diseases. Our core product REC603, a recombinant 9-valent HPV vaccine in Phase III clinical trial and has a leading research and development progress. Apart from that, ReCOV, a recombinant COVID-19 vaccine, has been recognized as one of the most competitive next-generation COVID-19 vaccines in the world. Recbio has a clear commercialization strategy aiming to penetrate the diversified global vaccine market.

JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatments of various diseases. The company has a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms.

科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发，并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 科兴制药主要产品包括重组蛋白药物"重组人促红素"、"重组人干扰素α1b"、"重组人粒细胞刺激因子"，微生态制剂药物"酪酸梭菌二联活菌"。公司主要产品已沉淀一定行业优势地位和市场影响力，近年来依托政策支持和营销渠道深耕，保持稳定增长。

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor and tumor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancers, alopecia and acne.

Kunming Longjin Pharmaceutical Co., Ltd. is a holding subsidiary of Yunnan CAS Longjin Biotechnology Co., Ltd. which serves as the polypeptide innovative drugs.

Kunshi Biotechnology is a privately held company located in Kunshan City, Jiangsu Province. The company is involved in high-level research and production in the biotechnology field.

Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment. Led by industry veterans with a strong passion for innovation, we aim to operate as an R&D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietary technology platforms and deep understanding of the tumor microenvironment. we have built a differentiated pipeline of products and are striving to progress our programs toward the clinic.

Leads Biolabs Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company. Since 2014, the company has been operating in the development of single-target antibodies and bispecific antibody new drugs. It has also announced worldwide license and collaboration agreements for anti-LAG-3 antibody and received FDA approval for IND application for bispecific antibody. Leads Biolabs is also involved in the development and manufacturing of mAb candidates in collaboration with Chime Biologics and BeiGene.

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics with a strong China foundation and global vision. Our mission is to become a leading innovative company serving the unmet medical needs of cancer patients with first-in-class and best-in-class drugs. We strive to continuously develop a market differentiating pipeline by combining in-house research and development and strategic collaborations, strengthen in-house manufacturing, and commercialize our pipeline products through dedicated sales and marketing forces in China as well as via partnerships internationally.

Likang Life Sciences is an innovative enterprise dedicated to development of immune cell therapy, with tumor-specific neoantigen as the target. It aims to provide personalized diagnosis and treatment services for cancer patients with the most cutting-edge precise detection and treatment methods. By now, the company has established close cooperative relationship with Chinese PLA General Hospital (301 Hospital), Beijing Cancer Hospital, and Cancer Hospital Chinese Academy of Medical Sciences, and is preparing several clinical trials. The company's goal is to establish a top cancer treatment center with advanced concepts, leading technologies and standardized services, and lead cancer treatment into a new era of personalized tumor immunotherapy.

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. The company’s lead development program is with catumaxomab, a clinically validated bispecific antibody which was the first approved T-cell engager, and its associated Triomab technology platform. LintonPharm, in collaboration with Lindis Biotech, is also developing a next generation bispecific antibody platform known as Fleximab which aims to provide better CMC developability and less immunogenicity. The LintonPharm pipeline includes several treatments in development for blood cancer and solid tumors that use the Triomab and Fleximab platforms. For more information, please visit www.lintonpharm.com.

Longbio Pharma is founded in 2018, and located in Zhangjiang Hi-tech Park, Shanghai. There are 40+ scientists, 10+years experiences in protein drug development (antibodies and fusion proteins) .The co-founder team successfully developed two drugs for marketing (accumulated global sales USD 30 Billion). Longbio Pharma is focusing on R&D the innovative drugs of autoimmune and rare diseases (allergy and complement).

Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgen’s most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen employs over 35 scientists with global pharmaceutical research and development experiences at its research sites in China and the USA.

The company makes vaccines and is currently working on a Shingles vaccine.

Medilink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and the latest generation of technologies and products. Founded in 2020, the company is dedicated to developing globally competitive conjugated drugs with a focus on therapeutic effect.

Shanghai Miracogen is a biotechnology company that offers development, clinical research, and industrialization of new products for the treatment of various diseases such as breast cancer and non-small cell lung cancer. The company is a clinical stage biotech company fully owned by Lepu Biopharma.

Nanjing Legend Pharmaceutical & Chemical Co., Ltd is a research-based pharmaceutical & chemical enterprise dedicated to the development, manufacture and marketing of novel products in pharmaceuticals and fine chemicals.Legend has technological competencies in asymmetric synthesis

NanoRibo, founded in May 2021, is a biopharmaceutical technology company specializing in mRNA-related research and development of innovative vaccines and drugs. Our founding team, with over 20 years of expertise in virology and vaccine research, has played pivotal roles in esteemed research institutions and multinational corporations (MNCs) worldwide with extensive involvement in mRNA research and development, granting us genuine mastery of the technical know-how in the mRNA field. NanoRibo boasts a solid foundation in pathogenic biology, immunology, molecular biology, and bioinformatics. We are dedicated to fostering original innovation and have created a cutting-edge platform for researching and developing mRNA vaccines and drugs. Our mission at NanoRibo is to pioneer the biopharmaceutical industry, excelling in innovation and thriving in the global market. We possess proprietary non-coding region sequences, codon optimization algorithms, antigen design and optimization methods based on AI/Deep Learning, circRNA purification processes, LNP lyophilization techniques, and other innovative solutions to industry challenges. Utilizing the advantages of our mRNA technology platform, we focus on addressing the pressing need for enhancing existing technologies or filling gaps in the market for vaccines and other immunotherapies.

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.

Neurodawn Pharmaceutical Co. Ltd. is an innovative company focusing on the development and industrialization of new drugs, with a focus on depression and anti-ischemic stroke brain cytoprotectant. They have developed drugs such as Y-2 sublingual tablet and Y-3 for depression, with a strong emphasis on efficacy and safety.

At Neurophth, we walk from obstacle to obstacle without loss of enthusiasm. 在纽福斯公司，我们是从一个障碍走向另一个障碍而不丧失热情。 We are China’s first gene therapy company for ophthalmic diseases. Our mission is building a brighter future for patients by innovative gene therapies. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and USA, we are striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. We leverage our AAV and CMC platforms to regain vision in patients suffering from Leber’s hereditary optic neuropathy (LHON), autosomal dominant optic atrophy, vascular retinopathy (wAMD, DME, etc), optic neuropathy (glaucoma, etc) and other genetic diseases. Our most advanced investigational candidate, NR082 (rAAV2-ND4), in development for the treatment of LHON associated with ND4 mutation using a single administration through less invasive intravitreal injection, has received orphan disease designations in the U.S. We are always seeking highly motivated and talented individuals with diverse experiences, abilities and interests who are seeking to inspire the world and help patients to restore vision to join us on our journey. To learn more about Neurophth and our open positions, visit www.neurophth.com.

A global biotech company commited to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need. We design novel CNS-tropic AAV capsids and innovative gene expression cassettes to achieve efficient, effective, and safe gene therapies for severe CNS disorders.

Developer of biotechnology focused on biopharmaceuticals. The company's innovative biologic drug anti-HER2 is a new generation of monoclonal.

Nutshell Therapeutics Inc. Inventing small molecule in the realm of drug discovery fostered by protein dynamics. Leveraging our cutting-edge technology based on protein dynamics, Nutshell

Oculgen Biopharma (Shen Zhen Oculgen BioMedical Technology Co. ,Ltd.) has a portfolio of the latest and best breakthrough ophthalmic treatment technology products covering the stages from early new drug target discovery, independent innovation, and commercialization. It hopes to address unmet clinical needs in the field of ophthalmic diseases and benefit global ophthalmic patients by providing innovative drugs in China, Asia, and around the world.

OnQuality Pharmaceuticals Ltd. is dedicated to and pioneering the development and commercialization of innovative drugs and drug delivery systems that improve the quality of cancer patients’ lives. By far, OnQuality has built a large pipeline to address unmet clinical needs in the area of oncology supportive care, with one asset in Phase II, three in pre-IND stage, and two others in the early development stage.

Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Overland Pharmaceuticals is a biopharmaceutical company founded in 2020, dedicated to developing innovative medicines for underserved patients in Asia and around the world. The company is supported by Hillhouse Capital and focuses on building a fully integrated biopharmaceutical platform through strategic collaborations in key disease areas. The company emphasizes advanced modalities, including in-house research and development and strategic partnerships. Overland Pharmaceuticals is particularly focused on creating an oncology portfolio that features first-in-class antibody-drug conjugates and allogeneic cell therapy programs, targeting the greater China and Asia markets through collaborations with established biotechnology firms. With international offices in Shanghai, Beijing, and Boston, Overland Pharmaceuticals leverages its strong network in Asia while engaging with global biotech innovation. The leadership team includes co-founders Hua Mu, MD, PhD, and Ed Zhang, MBA, both experienced executives in the life sciences sector. The company operates within a financially healthy range, indicating stability and growth potential in the biopharmaceutical industry.

Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem. Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs. Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Founded in 2008, Beijing PINS Medical Co., Ltd., is an innovative medical company specializing in R&D, production, and sales of full-range neuromodulation products, including stimulators for deep brain, vagus nerve, spinal cord, and sacral nerve. PINS Medical devotes itself to providing cutting-edge treatments for patients who suffer from neurological disorders such as Parkinson's disease, epilepsy, chronic pain, and uroclepsia. The name of PINS is derived from "Programmable Implanted Neuromodulation Stimulator" and is also an acronym of "patient is no. 1, always." This speaks to the goals of PINS Medical, which are to enhance patient well-being and restore hope, with a focus that goes beyond business to improving society for all citizens. As the incidence of neuropsychiatric disorders continues to rise, placing an increased burden on societies worldwide, PINS Medical, together with research centers, companies, and top academic scientists, will continue to develop the latest cutting-edge therapies and bring them to patients as rapidly and affordably as possible.

Shenzhen Pregin Biopharmaceutical Co., Ltd. is a national high-tech enterprise, Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and Shenzhen Special New Enterprise. Investor shareholders include the National Small and Medium Enterprises Development Fund and the National Science and Technology Commission of the Chinese Academy of Sciences. Jiahe Fund, Haier Capital, Shenzhen Capital Group, Winbond Health ( 002004), etc. It has been deeply involved in the field of cell and gene therapy drugs for many years.

Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation. The company’s mission is to use high-throughput, multiplexable genome editing in combination with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other important medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised three rounds of financing and is advancing its cell therapy programs into IND-enabling investigations.

Ractigen Therapeutics is an early-stage biotech company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

Recorna Bio is a researcher and developer of RNA-edited drugs, focusing on drug discovery and development by targeting RNA editing cutting-edge technology. The company has completed millions of USD in Angel round funding and collaborates with other RNA companies to discover novel therapies for lung disease.

Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world. The company is founded by industry veteran with deep expertise in RNA therapeutics program execution and world leading scientific advisors with rigorous biology understanding in the RNA space.

SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to address neurodegenerative and other CNS diseases. The company focuses on targets that are supported by human biology and which play a critical role in regulating foundation biology, to achieve better probability of success in clinical development. SciNeuro is committed to delivering medicines that can make a difference to improve the lives of patients around the world, transforming scientific discoveries into groundbreaking therapies.

Shanghai Henlius Biotech isabiopharmaceutical company in China that is developing biologics foroncology and autoimmune diseases.

Junshi BioPharma is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Our mission is to provide patients with treatment options that work better and cost less. Based on the core platform technology of protein engineering, Junshi stands at the frontier of R&D of macromolecular drugs. With distinguished capability of innovative drug discovery, advanced biotechnological R&D, large-scale production capacity on the full industry chain and rapidly expanding drug candidate portfolio of tremendous market potential, Junshi has a leading edge in the PRC in the emerging field of immuno-oncology and for the treatment of autoimmune and metabolic diseases. Junshi is the first PRC company filing IND application and NDA application to the NMPA for anti-PD-1 monoclonal antibody, and also the first PRC company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody. Our vision is to become a pioneer in the area of translational medicine by developing first-in-class and best-in-class drugs through original innovation. With enrichment of our product pipelines and exploration of drug combination therapies, Junshi expanded its innovation to the R&D of more types of drugs, including small molecule drugs and antibody drug conjugates (or ADCs), as well as to the exploration of the next-generation innovative therapies for cancer and autoimmune diseases.

Shanghai Pharmaceuticals Holding Co. Ltd. ("SPH") is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067) respectively. The company provides leading healthcare services in: Research & Development, Manufacturing, Distribution and Retail. In 2019, SPH reported revenues of US$26.5bn, making the company one of the country's major forces in the industry. SPH is one of the few listed pharmaceutical companies with a leading position in both manufacturing and distribution in China. It is included in the constituent stocks of the SSE 180, CSI 300 indices and MSCI.

SIMR is an innovation-oriented biopharmaceutical company dedicated to the discovery and development of new drugs for pain, inflammation and central nervous system related diseases. Since its establishment in 2014, the company has established a research and development platform of more than 3,000 square meters, with comprehensive drug development capabilities such as compound screening, CMC research, preclinical evaluation, and clinical development.

Shanghai Sunway Biotech is a biopharmaceutical company that develops, manufactures, and commercializes cancer biotherapeutics based on its oncolytic virus platform. The company has been involved in clinical trials and has received approval for oncolytic virus therapy for cancer treatment in China. Shanghai Sunway Biotech aims to provide innovative and effective treatments for cancer patients.

Shengke Pharmaceuticals is an international drug discovery engine focused on the discovery and development of targeted small molecule inhibitors, which could target cell cycle regulatory proteins, signal transduction networks as well as tumor microenvironment for the treatment of cancer and other diseases. Through multi-level partnerships and collaborations with global academic groups and industry experts, we are creating open research environments and devoted to translating molecular insights into better medicines. We are advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. Our core team members have a proven track record of important roles in the design and discovery of clinical candidates for the treatment of cancer and CNS disease.

Shenogen Pharma Group is a drug discovery and development company founded in 2006 at Beijing, China. Shenogen aims to develop and commercialize first-in-class therapeutics for cancer and autoimmune diseases. Our first and leading compound Icaritin is an excellent example of Shen Nong meeting Gene, as Icaritin is isolated from a traditional Chinese herb, and is currently being examined as a First-in-Class drug candidate in phase III clinical trial to treat liver cancer. Utilizing modern biotech platforms, novel targets and independent intellectual properties, we have successfully generated a rich research portfolio beyond Chinese herbs. Our new drug candidates ranging from small molecules, oncolytic viruses, to various forms of antibody based biologics, are being developed in stages from discovery to late clinical trials. Currently, we are establishing a full pharma value chain from research to production and commercialization. Our subsidiary companies focusing in different segments of the value chain are set up indifferent places in China including Beijing, Shandong, Hubei, Hunan, and Guangzhou. We are dedicated to bring our R&D innovations to the patients, and to providing them and their families with better health and better lives.

TargetRx is a clinical stage, high-tech pharmaceutical R&D company focused on developing next-generation targeted therapies for cancer patients, particularly those who are resistant or refractory to current treatments. TargetRx has developed a series of cutting-edge and efficient small molecule drug discovery platforms, which combine innovative research and development capabilities for drug design, screening, evaluation and optimization. Since its establishment, TargetRx has been granted over 170 patents from authorities in China, the US, Europe, Japan and other regions. Several potential best-in-class compounds are at different stages of multi-national clinical trials. BD Contact: shujun.mai@tjrbiosciences.com.

海思科医药集团成立于2000年，是一家以新药研发为核心，销售能力特别突出的医药类集团化上市公司。集团是肠外营养行业领导者，在肝病领域细分市场占据重要地位，是全国排名前列的肝病用药生产销售基地，现有员工超过1900名。 公司自2012年1月17日在深圳证券交易所A股上市以来，在资本市场有着良好的表现，目前股票市值约270亿人民币，A股排名前380、中小板排名前59、全国医药上市公司中长期排名25、化学药子行业上市公司排名第7 位、上市公司市值管理绩效百佳榜第9位、中国上市公司市值管理绩效百佳、中国医药行业最具影响力榜单成长50强企业、2014福布斯中国上市潜力企业100强位列第三位、医药类企业第一位、2015福布斯中国潜力企业。 公司坚持以新产品研发作为企业发展的核心驱动力，经过多年积累与实践，公司已建立450人的研发团队，其中包括50余名博士、近百名硕士，95%以上成员具有药学或相关专业本科以上学历，公司研发团队技术水平、团队人数在国内医药企业处于领先水平，公司首仿成功率行业第一，近五年新药批件取得数量全国第三。 公司于2015年正式进军高端医疗器械市场。

SinoMab BioScience Limited (stock code: 3681.HK) is a Hong Kong based clinical-phase biopharmaceutical company focus on the development of novel and high-value recombinant therapeutic proteins for treating various life-threatening and debilitating diseases in human.

An Unique TIDEs Platform with Cutting Edge Technologies As an industry leader in therapeutic peptides, Sinopep stands as the exclusive API supplier for Albuvirtide and Lanreotide 505b2—two of the top five in-demand peptide products. We are also the global leader in supplying Semaglutide, Tirzepatide, and Liraglutide, dominating the market in export quantity. Sinopep consistently delivers the highest quality peptide APIs, supported by comprehensive documentation that meets stringent global standards. Our advanced process development and manufacturing technologies ensure efficient production with high yields and some of the largest batch sizes in the industry. Additionally, Sinopep excels in providing efficient, flexible, and high-quality end-to-end CRDMO services across multiple modalities, including peptides, oligonucleotides, small molecules, and related synthetic conjugates. This makes Sinopep a trusted partner in the pharmaceutical and healthcare industries worldwide.

Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research.

SmartNuclide Biopharma is a biopharmaceutical company that focuses on discovering and developing innovative biologics used in nuclear medicine, with a world-leading research and development technology platform for domain antibody-radiopharmaceuticals.

Shuoxing Biotech is a biopharmaceutical company committed to the development of efficient and low-toxic multifunctional antibody medicines. Shuoxing Biotech is a biotechnology company based in China that has raised an undisclosed amount of money in funding.

Starna Therapeutics focuses on extrahepatic targeted delivery technology and is committed to developing innovative drugs with RNA as the core to solve unmet clinical needs. The core team comes from well-known pharmaceutical companies, universities and research institutes. The team has profound capabilities in nucleic acid drug discovery, delivery technology and formulation development.

The mission of the company is to develop innovative diagnostic reagents, cellular therapeutics technologies and engineered cell products to help

Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeutics as an effort to address unmet clinical needs in the world with the tools, capacity and RNA therapeutics that we build up in China. Fueled by our mission to make China's oligonucleotide therapeutics serve the world, we seek. Based on its cutting edge RNAi technologies, Ribo has established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization.

TCRCure Biopharma Corp is a world-class, “One-Stop Shop” cell therapy operation built across the U.S. and China. We deliver the latest cell therapy advances directly to patients with solid tumors. As of 2021, we have treated more than 50 patients and built more than a dozen CAR-T/TCR-T pipelines. TCRCure’s cutting-edge platform technologies include antigen-specific TCR/CAR discovery, immune-cell engineering, and industry-scale viral vector production. We operate 40,000 sq. ft. of specialized facilities on both sides of the Pacific, including scalable GMP capacity for cell production and viral manufacturing. TCRCure works closely with world-class hospitals in China and the United States for clinical research in different solid tumors. Current indications including cervical cancer, ovarian cancer, nasopharyngeal carcinoma, lung squamous carcinoma, melanoma, sarcoma, endometrial cancer, and brain cancer.

Was established in 1993 and is headquartered in the core area of ​​the Eastern Smart City of Guangzhou, covering an area of ​​50,000 square meters. It is the world's leading bioprotein biopharmaceutical company, focusing on the sales and development of biopharmaceuticals in the field of critical illness. and production. The company adheres to the core values ​​of "integrity, integrity; passion, perseverance; commitment, efficiency; care, participation; innovation, learning; cooperation, communication", and owns the national Class II new drug (domestic exclusive variety) Templuoan® (urinol for injection) The company has the exclusive distribution rights in mainland China for the world's first Class 1 new drug Kailikan® (Eurexalin for injection), and the first-line drug Bonroli (ibandronic acid injection) in the field of tumor bone metastasis treatment.

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of “first-in-class” or “best-in-class” new drug products.

Universe Pharmaceuticals INC is a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (“TCMD”) products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the “NMPA”), and we currently produce 13 varieties of TCMD products, which are sold in approximately 202 cities of 30 provinces in China. In addition, through our wholly-owned subsidiary Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), we sell not only our TCMD products, but also biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (“TCMPs”), and dietary supplements manufactured by third-party pharmaceutical companies.

VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier. In 2018, VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology therapies in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. In Jan 2021, VISEN had closed a $150 million Series B financing led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments.

Vitalgen is a biopharmaceutical company that focuses on the research and development of gene therapeutics.

Westlake Genetech (Hangzhou) Co., Ltd. is an innovative biotech company, a start-up from scientific research achievements of Westlake University. We focus on the rapid development of first-in-class drugs by integrating the 3H (high throughput, high precision, high dimension) biotechnological data production and deep learning modeling. By building technology-driven gene therapy technology platforms and developing differentiated self-developed gene therapy products, we are committed to mapping the full-process implementation of AI-powered gene therapy. Westlake Genetech adheres to the development strategy of "platform + pipeline" dual-wheel drive, actively invests in R&D innovation that combines technological leadership and industrial feasibility, and promotes the technological and commercial landing of AI technology in the vertical field of biomedicine. Our self-developed AI-powered full-chain gene therapy technology platform has evolved to generate a large number of non-liver-targeted AAV capsids, developed gene editing tools with independent intellectual property rights, explored new targets, and developed safe, efficient, and accessible gene therapy innovative therapies for rare diseases, tumors, and other diseases. With the platform's empowerment, it will effectively expand the scope of gene therapy indications, significantly shorten the pipeline development time, improve the pipeline R&D efficiency, and achieve the optimization of cost reduction and efficiency improvement and technology tool selection. We are rapidly advancing our technological achievements to the field of disease treatment, laying out ex vivo and in vivo gene therapy, developing differentiated gene therapy products, and solving more unmet clinical needs.

Xiamen Amoytop Biotech Co., Ltd., founded in 1996, is an innovative biopharmaceutical company in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for unmet medical needs, such as viral hepatitis and malignant tumors, and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB.

Xynomic Pharmaceuticals, Inc. is a US incorporated biopharmaceutical company founded by US-China industry veterans and successful entrepreneurs. Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.

亿帆医药股份有限公司是一家在深圳交易所A股上市的企业，证券简称：亿帆医药，证券代码：002019。 公司为医药创新型研发生产企业，设有亿帆研究院、国家级博士后科研工作站、省级企业技术中心（研发中心），旗下拥有多家高新技术企业，现有药学及相关专业硕士、博士逾百名，拥有双分子技术、免疫抗体技术两大先进生物药创新研发平台，已获国际及国内药品相关专利授权近百项，其中国际专利35项。 公司承担了国家"十五"攻关项目、国家高技术产业化示范工程项目、国家火炬计划项目等，曾荣获国家发明二等奖、国家科技进步二等奖各一项。 公司以专业性、专科性及治疗型重点专科领域产品线为导向，不断创新，转型升级，向大分子生物药、高端化药及特色中药等重点领域发展。拥有几十个在研高端化药，其中近10个已处临床或报产阶段；拥有妇科、儿科、皮肤科等药品批准文号400余个，其中独家特色中西药40多个，独家医保品种20余个。现有数个正处国际临床II期、III期的大分子生物药，是第一家大分子创新生物药在美国进入II期、III期临床试验的中国企业，将带领中国生物药叩响美国的大门。 公司已形成以安徽为主的小分子高端化药、植物药生产中心，以四川为主的皮肤科、妇科生产中心，以辽宁为主的骨科、治疗型大输液生产中心，以北京、上海为主的大分子生物药研发与生产中心及以浙江为主的原料药生产中心。 公司医药业务覆盖除港澳台以外的所有省市区，药品制剂在全国二级以上医院的覆盖率超过60%，同时作为世界较大的维生素B5及维生素原B5生产供应商，公司医用原料药销售网络辐射欧、美等多个国家和地区，全球市场占有率40%-45%，稳居龙头地位。 面向未来，公司将始终专注于医药、医疗健康事业，坚持"整合、创新、国际化"的发展战略，恪守"务实、创新、诚信、勤奋"的核心价值观，致力于为客户创造效益，为员工创造平台，为股东创造财富，为社会创造价值，持续成长为全球医药健康事业的专家。

YolTech Therapeutics is a biotech focuses on combining mRNA and gene editing technology to develop next-generation mRNA drugs and in vivo gene editing drugs.Our company is a pre-clinical stage gene editing biotech, has built leading genome editing platform and mRNA-LNP library. It possesses strong capability of novel Cas and base editors discovery and exceptional production capacity for LNP drug manufactory, with strong IP protection globally. It has created a pipeline with 10 genetic medicines focusing on cardiovascular diseases, infectious diseases and rare diseases.

Zensun develops and commercializes bio-therapeutic products for the treatment of cardiovascular disease and energy metabolism disorders.

Zhiyi is a leading company in live biotherapeutics (LBPs) and next-generation probiotics in China. The company’s SK08（Bacteroides fragilis） was approved for clinical trials in November 2019.It is the first LBP in China with immense influence. Zhiyi has established a complete technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. Zhiyi also has a complete industrialization platform from preclinical to NDA.

Zhiyi is a leading company in live biotherapeutics (LBPs) and next-generation probiotics in China. The company’s SK08（Bacteroides fragilis） was approved for clinical trials in November 2019.It is the first LBP in China with immense influence. Zhiyi has established a complete technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. Zhiyi also has a complete industrialization platform from preclinical to NDA.

Innovent Biologics Co is a biopharmaceutical company that focuses on developing innovative biotechnology solutions in the healthcare and pharmaceuticals industry.

公司的主营业务为特色原料药、医药中间体的研发、生产和销售，以及为客户提供定制加工和研发业务。产品具有手性结构多、研发难度大、技术壁垒高、生产工艺独特等特点。公司是高新技术企业，被认定为“省级高新技术企业研究开发中心”、“省级企业研究院”，公司拥有院士工作站、博士后工作站、博士后创新实践基地等优秀的研发平台，与诸多高校、研究所保持良好的研发合作关系。